Hong Zheng

Dr. Hong Zheng

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2021 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
YGYuqian Guo
Yuqian Guo
LWLimei Wang
Limei Wang
JLJiangli Lu
Jiangli Lu
JJJianlin Jiao
Jianlin Jiao
YYYi Yang
Yi Yang
HZHong Zheng
Hong Zheng
Ginsenoside Rg1 (Rg1) is traditional Chinese medicine with neuroprotective activity. Previous studies have demonstrated that Rg1 improves Alzheimer's disease (AD) and alters gut microbiology, but its mechanism remains to be elucidated, and thus far, its use in the treatment of AD has not been satisfactory. The present study investigated the improvement effects of Rg1 and its association with the microbiota of the large intestine. Following treatment with Rg1 in AD tree shrews, the treatment group demonstrated significantly shorter escape latency and crossed a platform more frequently in a water maze test. Western blotting demonstrated that Rg1 inhibited the expression of β-secretase 1, while increasing microtubule-associated protein 2 and Fox-3 in the hippocampus. Immunohistochemical analysis revealed that Rg1 decreased the expression of amyloid β, tau phosphorylated at serine 404 and pro-apoptotic factor Bax, while increasing the expression of Bcl-2 in the hippocampus and cortex. High throughput sequencing of 16S rRNA demonstrated that Rg1 altered the microbiota abundance of the large intestine. In conclusion, Rg1 affected the expression of apoptosis proteins, possessed a neuroprotective effect and may have a close association with the microbiota of large intestine by significantly reducing the abundance of Bacteroidetes and increasing the energy requirement of tree shrews.

27 June 2024 in Cell Biology International
Verified
Journal Article
Closed access
YYYi Yang
Yi Yang
RLRong Li
Rong Li
PWPeijin Wang
Peijin Wang
YZYulan Zhao
Yulan Zhao
JLJintao Li
Jintao Li
HZHong Zheng
Hong Zheng

6 August 2025 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
RLRong Li
Rong Li
JLJiangli Lu
Jiangli Lu
PWPeijin Wang
Peijin Wang
YZYulan Zhao
Yulan Zhao
YYYi Yang
Yi Yang
HZHong Zheng
Hong Zheng

17 January 2024 in Research Square
Verified
Preprint
Open access
PDF file
RLRong Li
Rong Li
JLJiangli Lu
Jiangli Lu
PWPeijin Wang
Peijin Wang
YZYulan Zhao
Yulan Zhao
YYYi Yang
Yi Yang
HZHong Zheng
Hong Zheng
Osteoking (OK) is a Yi folk Chinese herb from the Yunnan province, which exerts bone formation-promoting effects on menopausal osteoporosis and osteoporotic fractures. However, it remains to be determined whether OK ameliorates type 2 diabetic osteoporosis (T2DOP). Thus, T2DOP animal model was established in db/db mice in this study. Micro-computed tomography (micro-CT) analysis revealed that OK significantly increased bone strength, improved bone metabolism, and promoted bone formation. GS and p-GSK-3β expression levels were increased in OK group as compared with db/db group by Western blot analysis. IL-6, IL-17A, IFN-γ, TNF-α, and IL-1β were lower levels in the OK group compared to the db/db group, nevertheless, the IL-10 level was significantly higher. Furthermore, an In vitro cells model was constructed by stimulating with high glucose (HG, 30 mM). ALP protein was significantly elevated in OK treatment group. Administration of OK at 1.44 mg/mL significantly increased p-AKT/AKT expression, while, combined with LY294002, an inhibitor of PI3K, OK significantly reduced the expression levels of p-PI3K/PI3K, p-AKT/AKT and p-GSK-3β/GSK-3β. In conclusion, to our knowledge, this study is the first to reveal OK exhibits efficacy against T2DOP in db/db mice by promoting osteogenesis of preosteoblast MC3T3-E1 cells through PI3K/AKT/GSK-3β pathway regulation.